coronavirus vaccine developed by Russia's Vektor State Research Center of Virology has proved its efficacy during pre-clinical trials, news agency TASS reported, citing a top offical. "The Vektor Center’s unique peptide-based vaccine has demonstrated high efficiency during preclinical tests and is now undergoing clinical trials," the center’s director Rinat Maksyutov said.The clinical trials of Vektor's vaccine are scheduled to be completed in September, the news agency reported, citing the country's regulator.Earlier this month, on August 11, Russia registered the world’s first vaccine against the novel coronavirus, even before final trials.